CAS |
231277-92-2 |
Chinese Name |
拉帕替尼 |
English Name |
Lapatinib |
Synonym |
拉帕替尼;WR-2721;UNII-M487QF2F4V; |
Unit |
Bottle |
Purity |
HPLC≥98% |
Molecular Formula |
C29H26ClFN4O4S |
Molecular Weight |
581.06 |
Appearance |
Light yellow to yellow solid |
Storage |
Powder : 2-8℃, 2 years; In solvent(mother liquid): -20℃, 1 month; -80℃, 6 months |
Solubility |
Soluble in DMSO |
MDL |
MFCD09264194 |
EC |
EINECS 1806241-263-5 |
InChIKey |
BCFGMOOMADDAQU-UHFFFAOYSA-N |
InChI |
InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35) |
PubChem CID |
208908 |
SMILES |
O=S(CCNCC1=CC=C(C2=CC=C3C(C(NC4=CC(Cl)=C(C=C4)OCC5=CC(F)=CC=C5)=NC=N3)=C2)O1)(C)=O |
Description |
Lapatinib is a potent EGFR and ErbB2 inhibitor. |
Target Point |
EGFR |
Passage |
Angiogenesis;Protein Tyrosine Kinase/RTK; JAK/STAT Signaling |
Data Literature Source |
[1]. Mol Cancer Ther. 2001 Dec;1(2):85-94; Cancer Res. 2006 Feb 1;66(3):1630-9.
[2]. Chefrour M et al. Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants. Fundam Clin Pharmacol. 2012 Aug;26(4):530-7.
[3]. Wainberg ZA, et al. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res. 2010 Mar 1;16(5):1509-19.
[4]. Eryilmaz U, et al. S100A1 as a Potential Diagnostic Biomarker for Assessing Cardiotoxicity and Implications for the Chemotherapy of Certain Cancers. PLoS One. 2015 Dec 18;10(12):e0145418.
[5]. Rusnak DW, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther. 2001 Dec;1(2):85-94 |
Specification |
5mg 10mM*1mL (in DMSO) 10mg |